Neuraxpharm

6 articles about Neuraxpharm

• TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)

  8/1/2023

  TG Therapeutics, Inc. (NASDAQ: TGTX) (TG) and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announced an agreement for the ex-US commercialization of BRIUMVI® (ublituximab).

• Tris Pharma and Neuraxpharm Group Announce Partnership to Commercialize Tris' Quillivant XR and Quillichew ER in Europe

  12/8/2020

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and Neuraxpharm Group ("Neuraxpharm"), a leading European specialty pharma

• Neuraxpharm provides business update on a transformational year

  9/24/2019

  Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the central nervous system (CNS), provides a business update for the last twelve months.

• European CNS specialist Neuraxpharm launches first products in the United Kingdom

  7/31/2019

  Craig Bowen appointed as General Manager of Neuraxpharm UK

• Neuraxpharm, the European CNS Specialist, launches first probiotic product PS128™

  5/28/2019

  New collaboration between Neuraxpharm and Bened Biomedical expands portfolio of Consumer Healthcare products

• Invent Farma And Neuraxpharm Appoint New Group CEO

  10/4/2016